Is Summit Therapeutics Inc. (SMMT) a Buy, Sell, or Hold?
NASDAQ : SMMT
Summit Therapeutics Inc.
$13.66 USD
-$1.32 (-8.81%)
- Volume
- 8.15M
- Average Volume
- 5.25M
- Market Capitalization
- $10.6B
- P/E Ratio
- -12.20
- Dividend Yield
- 0.00%
- Price Target
- $23.00
- Year High
- $30.98
- Year Low
- $12.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.96
Company Overview
NASDAQ
Robert W. Duggan
Biotechnology
Healthcare
SMMT
265
US
USD
Liquidity Metrics
0.03
6.96
6.96
4.05
0.00
Sales & Valuation
-$
0.00
16.87
-26.07
-0.52
Profitability
-$1.44
-$1.08B
0.00%
0.00%
-204.33%
-113.81%
P/E Metrics
-12.20
0.26
0.26
Analyst Price Target & Rating
$23.00
$38.00
$15.00
2/5
21 Analysts
-40.61%
Financial Health Scores
31.82
2/9
$617.01M
$752.18M
$122.2M
-$856.04M
Key Metrics (TTM)
$10.2B
0.00
-11.92
6.96
-204.33%
-134.14%
-8.05%
-3.84%
0 days
Company Executives
| Name | Title |
|---|---|
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director |
| Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Robert W. Duggan | Co-CEO & Executive Chairman |
| Howard Jack West | Vice President of Clinical Development |
| Bilal Piperdi | Chief Medical Officer |
| Elaine Carla Stracker | Chief Legal Officer |
| Mahkam Zanganeh | Co-CEO, President & Director |
| Nathan LiaBraaten | Senior Director of Investor Relations |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance |
| Allen S. Yang | Head of R&D Strategy |
| Laura Q. Chow | Senior Vice President of Clinical Development |
| Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer |
| Dave Gancarz | Chief Business & Strategy Officer |
| Wang Clow Fong | Chief Biometrics Officer |
| Robert LaCaze | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Summit Therapeutics Inc. (NASDAQ:SMMT) Stock
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caus ... ed by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
2026-07-24 11:53:17
Summit Therapeutics Inc. (NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better than the consensus loss of 28 cents per share.
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
2026-07-24 10:11:11
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
2026-07-23 22:40:26
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Q2 Earnings Call Highlights
2026-07-23 18:07:25
Summit Therapeutics NASDAQ: SMMT executives used the company's latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company's cash position as it prepares for a potential U.S. regulatory decision later this year.
2026-07-23 16:05:00
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf.
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
2026-07-23 11:36:25
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
2026-07-22 16:30:00
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
2026-07-22 16:30:00
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
Frequently Asked Questions
-
What is the current Summit Therapeutics Inc. (SMMT) stock price?
-
Summit Therapeutics Inc.(NASDAQ:SMMT) stock price is $13.66 in the last trading session. During the trading session, SMMT stock reached the peak price of $30.98 while $12.55 was the lowest point it dropped to. The percentage change in SMMT stock occurred in the recent session was --8.81% while the dollar amount for the price change in SMMT stock was -$1.32.
-
SMMT's industry and sector of operation?
-
The NASDAQ listed SMMT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SMMT?
-
Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director
Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Robert W. Duggan | Co-CEO & Executive Chairman
Howard Jack West | Vice President of Clinical Development
Bilal Piperdi | Chief Medical Officer -
How many employees does SMMT have?
-
Number of SMMT employees currently stands at 265. SMMT operates from 601 Brickell Key Drive, Miami, FL 33131, US.
-
Link for SMMT official website?
-
Official Website of SMMT is: https://www.smmttx.com
-
How do I contact SMMT?
-
SMMT could be contacted at phone #617 514 7149 and can also be accessed through its website. SMMT operates from 601 Brickell Key Drive, Miami, FL 33131, US.
-
How many shares of SMMT are traded daily?
-
The average number of SMMT shares traded daily for last 3 months was 5.25M.
-
What is the market cap of SMMT currently?
-
The market value of SMMT currently stands at $10.6B with its latest stock price at $13.66